General
information
1st International Symposium on Deuterium Depletion is an international
conference, wishes to give the researchers and medical practitioners
a unique opportunity to get acquainted with this expanding new
expanding field of science and share their results and experience.
The conference primarily focus on the biological effects of
naturally occurring deuterium and its importance in cancer,
diabetes and aging, but the scientific committee welcomed any
other papers originating from basic research which reveal the
role of deuterium in the different regulatory systems of the
cells.
The basic concept of the conference is to gather all the scientists
from the world, who have carried out basic or applied research
on deuterium depletion, in order to share these results, experience,
scientific and clinical information with the participants of
the symposium and by these means to summarize this knowledge
for the other scientists and clinicians involved in this field
and other professional participants and share the basic rules
of the application of DDW in the clinical practice.
Main topics of the Symposium
・Deuterium
Depletion in Cancer Research and Oncotherapy
・Deuterium
Depletion and Diabetes Research
・Deuterium
Depletion in Anti-Aging Research
Language
・All
presentation will be in English
English-Hungarian
synchronous intrepretation will be provided.
Scientific Commitee
・Gabor
Somlyai Ph.D
・Gabor
Jancso D.Sc.
・Walther
Bild M.D.,Ph.D.
・Michael
Aschner M.D., Ph.D.
・Yury
Sinyak D.Sc.
Organizing Committee
Miklos
Molnar M.D., Ph.D.
Ildiko
Somlyai M.Sc.
Gabor
Somlyai Ph.D.
Gabor
Laskay Ph.D.
The official congress organizer agent for
the symposium
Connections2000 Event and Incoming Agency
H-1016
Budapest, Hegyalja ut 18.
Tel:
36-1-209-0380
Fax:
36-1-209-9334
E-mail:
conn2000@conn2000.hu
Web:
www.conn2000.hu
The official sponsor of the symposium
HYD LLC. for Cancer Research and Drug Development
Address:
H-1118 Budapest, Menesi ut 104. Hungary
Postal
address: H-1539 Budapest, P.O.B. 695. Hungary
Phone:
+36-1-381-0765, +36-1-365-1660
Fax:
+36-1-365-1661
E-mail:
info@hyd.hu
Web:
www.hyd.hu, www.preventa.org
Venue
of the symposium
・Ramada
Plaza Budapest Hotel
Arpad
fejedelem utja 94.
H-1036
Budapest
Web:
www.ramadaplazabudapest.hu
Directions
Budapest Ferihegy Airport (BUD): 22 kilometers (14 miles)
from the destination which takes approximate 30 minutes by car.
With public transportation: take the bus nr93 or nr200E
to K.banya-Kispest (metro line 3). Take the metro till Arpad Bridge
station than take the tram nr1 direction to Buda till the other
side of the bridge (Szt. Lelek ter).
Driving directions: From the airport head for Ulloi Street,
go to Hungaria Boulevard and then Karoly Boulevard, then across
the Arpad Bridge and the hotel is on the left hand side. Budapest
has an inexpensive and efficient public transport system with
easy links between the metro, HEV trains, buses, trams and trolleybuses.
Tickets can be bought from metro stations, kiosks andnewsstands.
Budapest in General
Facts and figures
Area
|
|
525
square kilometres |
Population
|
|
1
815 000 |
Population
density
|
|
3456
persons / kilometre |
Administrative
structure
|
|
23
districts |
Buda
|
|
comprising
one-third of the area of the city on the hilly, right bank
of the Danube |
Pest
|
|
comprising
two-thirds of the area of the city on the flat, left bank
of the Danube |
Islands
|
|
Obuda
Island, Margaret Island, Csepel Island |
Bridges
|
|
seven
public ones and two railways |
Useful
information
Important numbers
Ambulance |
104 |
|
Universal
inquires |
197 |
Police |
107 |
|
Inland
inquires |
198 |
Fire
Service |
105 |
|
International
inquires |
199 |
Auto
Club help number |
188 |
|
Speaking
clock |
180 |
Credit
cards |
The
list of most commonly used types: AMEX, Diners Club, Euro/Mastercard,
JCB, Visa. |
|
Electricity |
Hungary’s
electricity network operates at 220-240 Volts. Plugs are
the regular continental types. |
|
Public
Transport |
Budapest
has an efficient public transport network. In general the
buses, trams and trolleybuses operate between 4.30 am and
11.30 pm.
Tickets can be purchased in advance at metro stations, ticket
machines, tobacconists,
news-agents and also at our information desk in the registration
area of the congress.
You may be requested to show your validated ticket on all
public transport or at exit points of the metro by ticket
inspectors. For this reason it is better to keep your ticket
until the very end of your journey or until you have left
the metro station. |
1st
International Symposium on Deuterium Depletion
Scientific programme overview
1st
International Symposium on Deuterium Depletion |
9.30-10.00 |
Registration, welcome coffee |
10.00-10.05 |
Opening |
Section
1. |
Chairmen:
Prof. Dr. Yu. E. Sinyak, Prof. Dr. Gabor Jancso |
10.05-10.30 |
1
|
G.
Somlyai, G. Jancso, Gy. Jakli, M. Molnar,
G. Laskay, L.Z. Feher, L.G. Puskas:
NATURALLY OCCURRING DEUTERIUM IS ESSENTIAL FOR
THE NORMAL GROWTH RATE OF CELLS |
10.30-10.50 |
2
|
Prof.
Dr. Laszlo Boros, Prof. Dr. Ebrahim Azizi,
G. Jancso:
PHYSIOLOGICAL EFFECTS OF HEAVY WATER |
10.50-11.15 |
3
|
Dr.
Gabor Somlyai, Dr. Walther Bild, W. Bild,
V. Bild, I. Haulica:
ENVIRONMENTAL DEUTERIUM AND CELL PROLIFERATION:
IMPLICATIONS IN RADIOBIOLOGY
|
11.15-11.40 |
4
|
Yu.E.
Sinyak, A.I. Grigoriev:
RECOVERY AND USE OF DEUTERIUM-FREE WATER IN EXTENDED
SPACE EXPEDITIONS |
11.40-12.00 |
5
|
D.S.
de Avila, M. Aschner:
PROTECTIVEEFFECTS OF DDW IN CAENORHABDITIS ELEGANS |
12.00-13.00 |
Lunch |
Section
2. |
Chairmen:
Prof. Dr. Laszlo Boros, Prof. Dr. Ebrahim Azizi |
13.00-13.35 |
6
|
L.
Boros, G. Somlyai:
INTERMEDIARY METABOLISM AND MACROMOLECULE SYNTHESIS
IN RESPONSE TO DEUTERIUM DEPLETION IN PANCREATIC,
BREAST AND LUNG CANCER CELL LINES |
13.35-13.55 |
7
|
G.
Laskay:
CELL PHYSIOLOGICAL EFFECTS OF REDUCED DEUTERIUM
CONTENT IN THE LEAVES OF ELODEA CANADENSIS |
13.55-14.15 |
8
|
E.
Azizi, K. Akbarzadeh, A. Hosseini:
ANTIPROLIFERATIVE EFFECTS, CELL CYCLE ALTERATIONS
AND APOPTOSIS INDUCTION OF DDW ON Z47D AND HT-29
HUMAN CARCINOMA CELL LINES |
14.15-14.35 |
9
|
I.Stef.nescu,
T. Nicola, C. Mladin, R.Tamaian, V. Niculescu,
V. Feurdean, G. Ti.escu,
N. P.un:
STUDIES CONCERNING DDW USE FOR DEUTERIUM’S DEPLETION
IN ANIMAL ORGANISM AND FOR SYNTHESIS OF NEW NAPHTHOQUINONIC
ANTITUMORAL COMPOUNDS |
14.35-14.55 |
10
|
M.
Szabo, T.Berkenyi, G. Somlyai:
THE EFFECTS OF ADMINISTRATION AND LOCAL APPLICATION
OF DEUTERIUM DEPLETED WATER ON DOGS AND CATS
SUFFERING FROM SPONTANEOUS MALIGNANCIES
|
14.55-15.40
|
Coffeebreak |
Section
3. |
Chairmen:
Dr. Walther Bild, Dr. Gabor Somlyai |
15.40-16.00 |
11
|
M.
Molnar, K. Horvath, T. Danko, G. Somlyai:
EFFECT OF DEUTERIUM OXIDE (D2O) CONTENT OF DRINKING
WATER ON GLUCOSE METABOLISM IN STZ-INDUCED DIABETIC
RATS |
16.00-16.20 |
12
|
G.
Somlyai, I. Guller, K. Krempels, I. Somlyai,
A. Kovacs:
DEUTERIUM DEPLETION AS AN EFFECTIVE TREATMENT
OPTION FOR PROSTATE CANCER - STATISTICAL EVALUATION
OF A DOUBLE BLIND, RANDOMIZED PHASE II CLINICAL
TRIAL AND A RETROSPECTIVE STUDY ON PROSTATE CANCER
|
16.20-16.40 |
13
|
K.
Krempels, I. Somlyai,
M. Huszar, G. Somlyai:
A RETROSPECTIVE STUDY TO EVALUATE THE EFFECT OF
DEUTERIUM DEPLETION ON THE SURVIVAL OF METASTATIC
BREAST CANCER PATIENTS |
16.40-17.00 |
14
|
Z.
Gyongyi, F. Budan, I. Szabo:
LUNG CANCER AND DEUTERIUM DEPLETION. CLINICAL
AND EXPERIMENTAL DATA |
17.00-17.25 |
15
|
G. Somlyai, I. Somlyai, M. Huszar, K. Krempels:
MAIN RESULTS AND BASIC RULES OF THE HUMAN APPLICATION
OF DEUTERIUM DEPLETED WATER IN COMBINATION WITH
CONVENTIONAL ONCOTHERAPIES |
17.25-17.35 |
Closing |
18.00- |
Reception |
|
Biographies
Gabor Somlyai, Ph.D.
Gabor Somlyai graduated as a biologist at the University of
Szeged in 1982. Between 1982 es 1990 he worked for the Plant
Protection Institute of the Hungarian Academy of Sciences, Department
of Plant Pathology, within this time period from 1983 to 1986
he was a scholarship-holder of the Hungarian Academy of Sciences
as a postgraduate student for obtaining PhD. In 1988 he defended
his thesis in molecular biology. In the same year he was a DFG-scholarship
holder at Georg August University in Gottingen for 6 months,
from the end of 1988 Dr. Somlyai held a postdoctoral fellowship
at the University of Missouri (Columbia,Missouri, USA), where
he worked in the field of genetic engineering and gene mapping.
In the wake of Hungarian Nobel-prize winning researcher Albert
Szent-Gyorgyi, who said that the true cause of cancer should
be looked for at sub-molecular level,Somlyai began his investigations
in 1990 as a senior research fellow at the Hungarian Institute
of Oncology with the examination of whether the naturally occuring
deuterium . the heavy isotope of hydrogen . has any role in
the regulation of biological, i.e. intracellular molecular processes.
In 1993 he established HYD Ltd. with his partners to carry out
anticancer research based on his invention, drug development
based on the proprietary procedure of deuterium depletion and
to conduct drug registration.Between 1993 and 1997 he was the
scientific director of HYD Ltd., from 1997 he became the CEO
of the company. In 2000 his book entitled. Defeating cancer!”
appeared in Hungary, from that time it has been published in
omania, Japan, the USA, South-Korea and in China. Gabor Somlyai
is the author of numerous scientific publications in ungarian,
English and German languages and recognized speaker of domestic
and international conferences.
Gabor Jancso, D.Sc.
Gabor Jancso was born in 1941 in Budapest, Hungary. He graduated
with a degree in chemistry from Eotvos Lorand University in
1964 and immediately joined the Central Research Institute for
Physics of the Hungarian Academy of Sciences. He is currently
a Scientific Adviser at the KFKI Atomic Energy Research Institute
and holds a honorary professorship at the Eotvos Lorand University.In
1969-1970 and 1976-1977 he spent one-year study leaves at the
Chemistry Department of The University of Tennessee;from 1982
to 1984 he was a visiting scientist at the Max Planck Institut
fur Chemie in Mainz. His research interests include the investigation
of the effects of isotopic substitution on the properties of
liquids and mixtures, molecular dynamics simulation of liquid
water and aqueous solutions, and studies of the effects of intermolecular
interaction on the vibrational properties of molecules in the
condensed phase. More recently he has become involved with studies
of the structural and dynamic properties of aqueous solutions
using neutron diffraction. He is coauthor of more than one hundred
twenty papers.
Walther Bild, Ph.D.
Graduate of the Faculty of Medicine, University of Medicine
and Pharmacy “Gr T. Popa “, Iasi, Romania, in 1991. Scientific
research begins in the Romanian Academy, as an employee of the
Experimental and Applied Physiology Laboratory, led by the reknowned
scientist I Haulica (member of the Romanian Academy). Since
1998 became also part of the teaching staff at the University
of Medicine and Pharmacy. From 1996 he begins doctoral studies
in the biophysics of radiobiology. In 2005 became a specialist
in nuclear medicine, took charge in 2009 of the Experimental
and Applied Physiology Laboratory and holds the position of
associate professor in the Department of Fundamental Sciences,
University of Medicine and Pharmacy “Gr T. Popa “, Iasi, Romania.
Since 1998 begins the collaboration with the first provider
of DDW, the Institute of Cryogenics and Isotopic Research for
expanding research in several directions, including the study
of immunological effects, investigation or histological changes
or of vascular reactivity induced by prolonged administration
of DDW. In the period 1999-2000 is beneficiary of a scholarship
from the Pharmacological Association Berlin-Brandenburg which
allows the investigation of the cellular effects of various
concentrations of DDW within the Department of Immunology Center
for Molecular Medicine “Max Delbruck” in Berlin. Since 2000
the research took also a contractual form, the Laboratory of
the Academy became a subcontractor in a national grant to study
the biological effects of DDW within several research units.
By 2004 he published 6 papers in extenso and presented 14 domestic
and international communications regarding the biological effects
of DDW. In 2002 he was part of the gold medal winning teams
at the International Exhibition of Inventions, Geneva for “Biological
Radioprotection” and also the gold medal at the Salon of Inventions
“Eureka”,Brussels, for “Immune Activation”. Also has filed two
patents for these innovations. His studies focused on the radioprotective
effects and the investigation of the mechanisms by which they
can be achieved. During recent years it has been demonstrated
the hiperproliferative effect on cells in culture, the immunostimulating
effect in vivo and in vitro and the stimulating effect of membrane
proton pumps and intracellular alkalinization as a mitosis triggering
factor. Currently is still studying the biological effects of
isotopic ratios alteration (using radioactive and non-radioactive
isotopes) employing methods of electrophysiology and cell biology.
Yury
Emelyanovich Sinyak, D.Sc.
Yury Sinyak was born 30 march 1932. Graduated in 1955 from chemical
faculty of Gorky State University on speciality radiochemistry
In 1955 - 1958 he postgraduate in Institute of Physical Chemistry
of Academy of Sciences USSR and graduated with a Candidate of
Chemistry Sciences degree. In 1961-1963 Yu. Sinyak - senior
research assistant of Institute of Space Medicine, in 1963-2010
head of laboratory, head of Department of Life Support Systems
in Institute for Biomedical Problems. In 1972 Yu.Sinyak defended
the dissertation on degree of Doctor of Technical Sciences,
in 1977 he was given rank Professor on speciality Physical Chemistry.
From 1961 Yu. Sinyak have been developed the technologies for
regenerative physical-chemical life support systems for crews
of space ships and orbital space stations. Some technologies
of Yu. Sinyak was used to creating of regenerative water supply
systems for orbital space stations “Salut”, “MIR” and “ISS”
(such systems as “SRW-C”, “SRW-U” etc.). Yu. Sinyak have been
developed the structure of ecological life support systems based
on biological-physical-chemical methods. In during last years
Yu. Sinyak have been developed a new scientific direction: life
support systems for creating and supporting of environment with
optimal isotope composition of biogenic chemical elements (H2,
O2, Ca, Mg etc.), including plants, animal and man. The main
goal of such life support systems consist of removal of the
heavy stable isotope (such as deuterium, 18O etc.) from water,atmosphere,
plants, animals and man. He have developed the technology for
recovery of the water with the lowered concentration of deuterium,
based on the electrolysis of distilled water. Deuterium-free
water has been used for: cultivation of the higher plants, breeding
of birds . quails, research of anti-tumor properties, research
of radiation shielding properties. It was shown, that deuterium-free
water (and water with decreasing concentration of 18O2) provide
positive medical-biological activity. Yu. Sinyak is author of
more 300 sciences works, including manuscripts, monographs and
patents.Yu. Sinyak is awarded with the order “Znak Pocheta”,
he is Gagarin and Korolev Medalist of the Russion Cosmonautics
Agency.He is academician of International Academy of Astronautics,
Russian Academy of Cosmonautics named after K.E. Tsiolkovsky
and Academy of Technological Sciences of Russion Federation,
Honoured Inventor of Russion Federation, Honoured Scientist
of Russion Federation and Russian Government Prize Laureate.
Michael Aschner, Ph.D.
Dr. Aschner earned his B.S. from the University of Rochester,
Rochester, NY, in 1980, and his Ph.D. in Anatomy and Neurobiology
from the University of Rochester School of Medicine and Dentistry,
Rochester, NY, in 1985. After a brief postdoctoral fellowship
in Toxicology (at the same Institution), he assumed his first
faculty position (Assistant followed by Associate Professorship)
in the Department of Pharmacology at Albany Medical College,
Albany, NY (1988-1994). For the next decade he joined the Department
of Physiology and Pharmacology at Wake Forest University School
of Medicine, Winston-Salem, NC. As of 2004, Dr. Aschner serves
as the Gray E. B. Stahlman Professor of Neuroscience in the
Department of Pediatrics at the Vanderbilt University Medical
Center in Nashville, TN. He also holds joint appointments at
the Kennedy Center for Research on Human Development and in
the Department of Pharmacology. Dr. Aschner has served on numerous
national and international toxicology panels (Institute of Medicine,
US Environmental Protection Agency, Center for Disease Control),
served and chaired a National Institutes of Health study section,
and has authored approximately 300 peer-reviewed manuscripts
and chapters in the area of neurotoxicology. He serves as Associate
Editor (Neurotoxicology; Toxicological Science) and on the Editorial
Boards (Toxicology; Acta Neurobiologiae Experimentalis; Alcohol)
of several journals. He is a member of the Society of Toxicology,
Society for Neuroscience, a Fellow of the Academy of Toxicological
Sciences and a past president of the International Neurotoxicology
Association. Dr. Aschner’s research interests are in the neurobiology
and physiology of astrocytes and the mechanisms of central nervous
system injury. Dr. Aschner has been particularly interested
in metal uptake and distribution in the brain, devoting the
last 25 years of his research to the mechanisms of transport
of methylmercury, manganese, and uranium across the capillaries
composing the blood.brain barrier,as well as their cellular
and molecular mechanisms of neurotoxicity. Studies in the lab
address basic mechanisms in various experimental models (C.
elegans, tissue cultures and rodents) as well as follow-up on
the sequalae of manganese deposition in the brains of human
neonates. Most recently studies with DDW in the C. elegans model
established its protective role against Mn toxicity and aging,
likely by attenuating Mn-induced reactive oxygen species generation.
The effect of DDW appears DAF-16 dependent, increasing the expression
of antioxidants proteins and lifespan in C.elegans.
Daiana Silva de Avila, Ph.D.
Dr. Avila earned her bachelor in Pharmacy and Biochemistry from
the Federal University of Santa Maria (RS, Brazil) in 2005 and
her Ph.D from the Toxicological Biochemistry Program at the
same university in 2009. Dr. Avila assumed a postdoctoral position
in Dr. Aschner laboratory in 2009, where she is currently developing
her projects. Dr. Avila has been interested in the toxicity
of several toxicants and evaluating the effects of antioxidants
in the central nervous system using the rodent and the C. elegans
as experimental models. She is currently engaged in studying
the role of heat shock proteins and Parkinson´s disease related
genes in manganese (Mn)-induced neurotoxicity using C. elegans.
Recently, she assisted the Hydra group to elucidate the anti-aging
effects of the deuterium depleted water (DDW) using the C. elegans
model. Thus far, the group has found that DDW can restore the
Mn-induced decrease in lifespan in C. elegans. They also found
that restoration in the DAF-16 levels, a protein associated
with antioxidants production, prolonged the life span in C.
elegans.
Laszlo
Boros, M.D., Ph.D.
Dr. Boros holds a Doctor of Medicine (M.D.) degree from the
Albert Szent-Gyorgyi School of Medicine from Szeged, Hungary.
Dr. Boros currently is an Associate Professor of Pediatrics,
Endocrinology and Metabolism at the UCLA School of Medicine
and Chief Scientific Advisor of SiDMAP, LLC. Dr. Boros is the
co-inventor of the stable isotope-based dynamic metabolic profiling
(SIDMAP)technology and its applications for drug testing that
involves library screening, lead optimization and in vitro and
in vivo phenotype profiling of living cell and host systems
via flux measurements using heavy isotope labeled substrates
with 13C or 2H (deuterium). His primary interest is mechanisms
of drug resistance in pre-clinical drug testing studies using
detailed analysis of the metabolic network. He trained as a
house staff in his medical school in gastroenterology after
receiving a research and training fellowship from the Hungarian
Academy of Sciences, after which he was a visiting Scholar at
the Essen School of Medicine in Germany. Dr. Boros also worked
as a Research Scientist at the Ohio State University Department
of Surgery. Dr. Boros is the recipient of the C. Williams Hall
Outstanding Publication Award from the Academy of Surgical Research
of the USA (1997), the Richard E. Weitzman Memorial Research
Award from the University of California (2001) and the Excellence
in Clinical Research Award from General Clinical Research Center
at the Harbor-UCLA Medical Center (2004). Dr. Boros is an active
member of the American Association for Cancer Research, the
American Pancreatic Association, the American Physiological
Society and the American Gastroenterological Association. Dr.
Boros is currently serving on the Editorial Boards of the journals
Pancreas and Metabolism as well as on various peer review panels
including Hormone & Metabolic Research, Engineering Research
Council of Canada, Molecular & Cellular Biochemistry, Analytical
Biochemistry, Dutch Cancer Society (Nederlandse Kankerbestrijding),
Oncogene, Nutrition & Cancer as well as the Federation of
European Biochemical Societies (FEBS) Letters.
Gabor Laskay, Ph.D.
Dr. Laskay graduated as a biologist from the University of Szeged
in Hungary in 1979. He started work at the Department of Biophysics,
University of Szeged in 1979 and received his Ph.D. degree in
Biophysics from the University of Szeged in 1981. His Ph.D.
thesis was about the effect of the lipid environment on the
functions of the photosynthetic apparatus in plants. Dr. Laskay
did a 4-year post-doc at the Paterson Institute for Cancer Research
in Manchester, U.K., from 1988 to 1992, where he was involved
in various fluorescence studies comparing normal and cancer
cells. In the meantime he received his Candidate degree (then
a go-in-between Ph.D. and D.Sc.) in 1988. Later on dr. Laskay
worked at the Department of Medical Chemistry, Medical School,
University of Szeged, where he was involved in fluorescence
studies related to Alzheimer’s disease. He had the chance to
work at the Physiology Research Group, Limburg University in
Belgium from 1996 to 1999 where he studied Ca2+-homeostasis
in neural cells using fluorescent dyes. Since 1996 he has been
an Assistant Professor at the Department of Botany (since 2007
Department of Plant Biology) where he teach the courses of Cell
Biology, Plant Cell Biology, Fluorescence in Cell Biology, Cell
Death Mechanisms. Dr. Laskay has published 35 listed scientific
publications with a cumulative impact factor of 46.345, and
have written a university lecture note (“Plant Cell Biology”),
which has been published in 3 consecutive editions and has sold
in more than 3,000 copies.
Ebrahim Azizi, Pharm.D., Ph.D.
Dr. Azizi got his Doctoral degree in Pharmacy in 1988 from Faculty
of Pharmacy, Tehran University of Medical Sciences which is
the first rank in the country. Then he was employed as instructor
of Pharmacology and Toxicology in the same faculty shortly after
graduation in 1988. Dr. Azizi started his PhD in the field of
cancer genetics and chemotherapy in 1992 and finished with honor
degree in 1997. Then he became Assistant Professor and Director
of Molecular Research Lab of same faculty. In 2006, he was promoted
to Associate Professor and in early 2010 to Full Professor.
In addition to teaching Pharmacy and PhD students the theory
and practical aspects of cancer genetics and chemotherapy, he
is supervising and coordinating research projects, thesis and
dissertations of qualified students. His research interests
are as followings:
1) Genetics of tumor cells with respect to Drug Resistance,
Apoptosis and Cell Cycle
2) Pharmacogenetics/genomics related to Population Variation
in Drug Responses
3) Evaluating of New Synthetic or Plant derived compounds for
Cancer Therapy at Cellular and Molecular level His experiences
in the field of DDW started 2 years ago when he received an
invitation from R&D office of Food and Drug Administration
of the Ministry of Health and Medical Education to study the
anticancer properties of DDW. The project involved both cellular
and molecular experiments to elucidate more on potentials of
DDW in cancer therapy as reported by Prof. Somlyai and colleagues.
The results that will partly be presented in the DDW Symposium
were promising and therefore, they decided to continue this
project at different aspects. Currently, they are doing experiments
to further evaluate the Antioxidant properties of DDW in cancer
cells in vitro as well as in Rats in vivo. As an academic member
in the Medical Sciences, dr. Azizi sincerely does hope with
close international collaborations and efforts, a new therapeutic
gift will be presented to cancer patients around the world.
He also highly appreciates valuable scientific contributions
of Prof. Somlyai and colleagues related to DDW potential medical
applications.
Radu
Tamaian, B.Sc.
Radu Tamaian graduated as a bachelor in biology and geology
at the Babes-Bolyai University in Cluj-Napoca (Romania) in 2000.From
2003 he is a PhD Student in Science (Biology) at the Faculty
of Biology, University of Bucharest, Romania. Radu Tamaia has
been employed at National Research and Development Institute
for Cryogenics and Isotopic Technologies . ICIT Rm.Valcea, Romania
since October 2000. Between 2000 and 2007 he was responsible
for the monitoring and microbiological control of the production
of deuterium depleted water (light water). Starting with 2002
he has been involved in research as following: Investigation
of hydrogen’s transport in atmosphere-soil-plants structures
using natural isotopic tracers; Studies of hydrogen’s isotopes’
translocation and accumulation in plants; Experimental researches
in the field of deuterium depleted water (DDW) effects over
laboratory animals’ health (toxicology, immunology and oncology);
Determination of deuterium’s distributions by mass-spectrometry
in laboratory and farm animals under effect of DDW; Experimental
researches in the field of natural drugs and synthetic therapeutics
(antitumoral compounds derivated from naphthoquinone ligands
using DDW as solvent). National projects in the field of hydrogen’s
isotopes and deuterium depletion: The determination and use
of biological effects of deuterium depleted waters on some animal
organisms in normal and pathological conditions (scientific
responsible); Methods of prevention and treatment for cancer
at humans and big animals (project responsible).; The investigation
of hydrogen’s transport in atmosphere-soil-plants structures
using natural isotopic tracers (project responsible).;The study
of hydrogen’s isotopes’ translocation and accumulation in plants
(project responsible); Hydrological studies using isotopic tracers
(team member); Transfer and technology development to obtain
deuterium depleted water and its derivatives (team member).
His undergoing project: Obtaining and characterization of new
targeted-nanodrugs with naphtoquinonic active substance (project
director).
Miklos Molnar, M.D., Ph.D.
Miklos Molnar graduated as a bioengineer at the Budapest University
of Technology and Economics in 1979 and earned his M.Sc.degree
as chemical engineer at the same university in 1981. He graduated
as a medical doctor at the Semmelweis University Faculty of
Medicine in 1988. In 2001 he received Ph.D. degree in Pathophysiology
at Semmelweis University Faculty of Medicine.Between 1985 and
1986 he was a Research Assistant between 1989 and 1991 a Postdoctoral
Fellow at the Dept. of Obstetrics and Gynecology at St. Louis
University, St.Louis, USA. Between 1988 and 1992 dr. Molnar
was an intern at the Institute of Pathophysiology at Semmelweis
University Faculty of Medicine. In 1992 and in 1996 he held
a Visiting Professor position at the Dept. of Obstetrics and
Gynecology at St. Louis University, St.Louis, USA for 2 months.
Between 1992 and 1993 he was an assistant lecturer at the Institute
of Pathophysiology at Semmelweis University Faculty of Medicine.
In 1998 he was a visiting professor at the Dept. of Physio-Pharmacology
at St. Louis University, St.Louis, USA for 2 months. Between
1993 and 2001 he was an Assistant Professor at the Institute
of Pathophysiology at Semmelweis University Faculty of Medicine.
Since 2001 he has been an Associate Professor at the Institute
of Pathophysiology at Semmelweis University Faculty of Medicine.
Dr. Molnar is the recipient of numerous awards and honors. He
has been a council member of the Hungarian Physiologic Society
since 1999. Dr. Molnar is the author of 60 original articles,
the total number of his publications is 126.
Krisztina Krempels, M.D.
Krisztina Krempels graduated as a medical doctor in 1991 from
the Semmelweis University Medical School in Budapest, Hungary.She
joined as a medical student in the neuroendocrine research team
at the 2nd Department of Anatomy of the Semmelweis University
in 1987; and participated in the research of cellular and molecular
aspects of the regulation of pituitary function and the hypothalamic
regulation also after her graduation as an assistant professor.
She gained teaching experience in anatomy, histology and embryology
both at the Hungarian and German language course of medical
students at the gross anatomy and histology laboratory classes,
and lectures. Getting a postdoctoral fellowship at the National
Institute of Neurological Disorders and Stroke in Bethesda,
Maryland U. S. A. between 1994 and 1996 she investigated the
distribution of somatostatin receptor mRNAs using in situ hybridization
and immunohystochemical techniques. At the Human Serum Production
& Medicine Manufacturing Co. Ltd., (Godoll., Hungary) she
took part in planning of bioequivalence studies from 1997. Since
2004 she has been working for the HYD LLC for Cancer Research
and Drug Development and gained experience using the novel proprietary
procedure of deuterium depletion for the treatment and prevention
in various types of cancer.
Zoltan Gyongyi, Ph.D.
Zoltan Gyorgyi graduated at Kossuth Lajos University as
a biologist in Debrecen in 1996. From 1996 he was a Ph.D. student
at Szent-Gyorgyi Albert Medical University, Szeged, Hungary
and at the University of Pecs from 1998. He earned his Ph.D.
degree from the University of Pecs in 2003. Between 2003 and
2006 he was a postdoctoral fellow at CNRS UMR (Reserch Training
Network) in Nice, France. From 2001 he was an assistant lecturer,
from 2004 a lecturer at the Public Health and Preventive Medicine,Medical
School, Pecs University, Hungary. His fields of interests are
the Molecular mechanisms of life, Carcinogenesis and Cancer
prevention. He is the author of 15 scientific papers (impact
factor 30, citations 53). His papers in the field of deuterium
depletion:Virag V, Varjas T, Gyongyi Z, Somlyai G, Ember I,
Nadasi E: The possible role of natural products in the dietotherapy
of cancerrelated weight loss: an animal model. ACTA ALIMENTARIA
36(2): 249-256, 2007., Gyongyi Z, Somlyai G: Deuterium depletion
can decrease the expression of c-myc Ha-ras and p53 gene in
carcinogen-treated mice. IN VIVO 14(3): 437-439, 2000. Their
main results of deuterium depletion research: Regulation of
genes, playing a key role in the cell cycle regulation and tumour
development, is sensitive to deuterium depletion according to
animal experiments.
Abstacts
Naturally occurring deuterium is essential for the normal
growth rate of cells
1G. Somlyai, 2G.
Jancso, 2Gy. Jakli, 3M.
Molnar, 4G. Laskay, 5L.Z.
Feher, 6L.G. Puskas
1 HYD LLC. for Cancer Research and Drug
Development, Budapest, Hungary, 2KFKI Atomic Energy Research
Institute, Budapest, Hungary, 3Semmelweis University Medical
School, Budapest, Hungary, 4University of Szeged, Department
of Plant Biology, Szeged, Hungary, 5Avidin Ltd, Szeged, Hungary,
6Biological Research Center of the Hungarian Academy of Sciences,
Laboratory of Functional Genomics, Szeged, Hungary,
The role of naturally occurring D in living organisms has been
examined by using deuterium-depleted water (DDW) (30-100 ppm)
instead of water containing the natural abundance of D (150
ppm). DDW significantly decreased the growth rate of L929 fibroblast,
HT-29 colon, A4, MDA and MCF-7 breast, PC-3 prostate, M19 melanoma
cell lines. The inhibitory effect was more significant when
the D-concentration of the culture medium was gradually decreased
in 3-5 steps. To investigate the anticancer effect of DDW in
vivo, human breast adenocarcinomas; MDA and MCF-7 were transplanted
into CBA/Ca mice. The drinking water of the animals in the treated
group (17) was replaced with DDW (30 ppm) one day after transplantation.
Eighty days after the transplantation all mice in the control
group perished (10) except one, meanwhile 70% of the animals
(12) were still alive in the treated group. In an other experiment,
PC-3 tumorous prostatic cells were transplanted into CBA/Ca
mice. The DDW treatment started on the 18th day. Twelve days
later the tumors were removed from mice and histologically examined.
Cells being in mitosis and apoptosis were counted. It was found
that in the control group, that received water with normal (150
ppm) D-content, 3.6% of the cells were in mitosis and only 1%
in apoptosis. The ratio was almost the opposite in the treated
group, where only 1.5% of the cells were in mitosis, while 3%
of the cells were in apoptosis. In order to reveal the molecular
background of the inhibitory effect of DDW COX-2 gene expression
was investigated in healthy myometrial and HT-29 colon tumorous
cell line in medium with 20-80-150-200-500-1000 ppm D. It was
found that deuterium depletion inhibited COX-2 expression and
the inhibition correlated with the D-concentration. At the same
time there was a strong correlation between the COX-2 expression
and the intracellular prostaglandin concentration. When the
prostaglandin was added back to the culture medium it diminished
the inhibitory effect of DDW. The application of DDW also proved
to influence the expression of genes encoding different kinases
using nanocapillary quantitative real-time PCR analysis technique
and to modify the activity of amilorid- sensitive Na+/H+ antiport
system. We suggest that cells are able to regulate the D/H ratio
and its changes can trigger certain molecular processes. One
possibility to modify the D/H ratio is the activation of the
H+-transport system which prefers to eliminate H+ resulting
in a higher D/H ratio within the cell. We suggest that the changing
D/H ratio can simultaneously regulate the expression of certain
genes and the activity of enzymes having key role in cell cycle
regulation and in other molecular mechanisms. We suppose that
the naturally occurring D is the key element of a hitherto unknown
sub-molecular regulatory system (SMRS).
Physiological Effects of Heavy Water
Gabor Jancso
KFKI Atomic Energy Research Institute, Budapest, Hungary
Since the discovery of deuterium on Thanksgiving Day, 1931,
the effect of heavy water (D2O) on various
living organisms has been widely investigated. The availability
of heavy water in the mid-1950’s in quantities of hundred tons
at a reasonable price greatly facilitated the research on the
effects of deuterium in biological systems. The physiological
effects of heavy water will be demonstrated on some selected
examples.
There are some striking effects of heavy water on simple organisms.
While early experiments indicated that the incorporation of
deuterium into algae was incompatible with life, it turned out
later that by gradually changing the deuterium concentration
of water in media used for growing algae can be fully adapted
to growth in D2O. Another example is the
mold Aspergillus niger which grows well in media containing
D2O, but loses its ability to synthesize
its characteristic black pigment and becomes alabaster-white.
Whereas simple organisms can be adapted to grow in D2O,
higher (vascular) plants as well as animals resist full euteration.
Experiments carried out with mice showed that animals drinking
30% D2O, and deuterated to about 25% in
the body fluids, live normal life span, however their reproductive
capacity becomes severely impaired. Deuterium content of 15-20%
in the body fluids was found to be the threshold for toxicity
in animals. Since deuterium substitution results in a decrease
of the rates of reactions the question arose already at an early
stage after the discovery of deuterium whether the growth of
tumors could be inhibited by the administration of heavy water.
Experiments carried out on mice with lyphosarcoma and mammary
cancer showed that although the administration of 40% D2O
decreased the growth rate of the tumors, the mice treated died
more rapidly due to the toxic effects of deuterium.
It is an interesting question how toxic deuterium or heavy water
is to humans. If it is accepted on the basis of animal experiments
that the “critical” deuterium concentration (the double of which
would cause severe physiological effects) is about 10%, then
one can easily estimate that a person of 70 kg may drink 4.8
liter heavy water without serious consequences. Thus heavy water
cannot be considered toxic to humans. This is an important conclusion
since heavy water is widely used for the estimation of total
body water.
It has been shown that the effect of heavy water, and thus of
increased deuterium concentration, on various physiological
processes has been extensively investigated. However, until
1993, when it was demonstrated by Somlyai and his co-workers
that sub-normal deuterium concentration leads to the inhibition
of cell division in cultured proliferating animal cells, very
little was known about the sensitivity of biological processes
to deuterium depletion.
Environmental
deuterium and cell proliferation: implications in radiobiology
1,2W. Bild, 1,2V.
Bild, 2I. Haulica
1 University of Medicine and Pharmacy,
Iasi, Romania
2 Laboratory of Experimental and Applied
Physiology of the Romanian Academy, Iasi, Romania
Knowing the radio-mimetic effects of deuterated water (heavy
water) and having a tool for achieving the partial depletion
of deuterium (deuterium-depleted water), the effects of chronic
administration of this water were tested in animals, which were
then subjected to irradiation with gamma radiation in various
doses.
Deuterium depleted water (DDW) demonstrated to be an effective
way to significantly reduce the deuterium concentration in animals
subjected to prolonged treatment. Deuterium concentration decreased
to about 90 ppm, compared to a normal concentration of about
140-145 ppm deuterium/protium.
Prolonged treatment with DDW significantly protects animals
from irradiation with n radiation at LD50 dose. The dose modifying
factor (DMF) could be calculated at 1.41. The association with
the strongest current chemical radioprotective (amifostine)
did not increase significantly the effects of treatment with
DDW. Protective effects were present also while administrating
LD50 of a chemical radiomimetic preparation derived from nitrogen-yperite
(hydrochloric embihine).
The antioxidant action is present but not strong enough to explain
the radioprotective effects reported. The strongest action was
unspecific stimulation of immunologic parameters.
The investigation of the mechanisms by which the stimulatory
action could take place in the rapidly proliferating cellular
compartments (hematopoetic and gastrointestinal mucosa) using
DDW as medium for normal and neoplastic cells in culture showed
significant effects of cell proliferation stimulation. The study
of the mechanisms that stimulate proliferation demonstrated
the possible involvement of K+/H+ ATP-ase in the mechanisms
that regulate cell division.
In conclusion, DDW can be regarded as a radiobiologically active
substance.
Recovery and use of deuterium-free water in extended space
expeditions
Yu.E. Sinyak, A.I. Grigoriev
State Scientific Center of Russian Federation-Institute for
Bio-Medical Problems
of the Russian Academy of Sciences, Moscow, Russia
On long space flights (for example, the Lunar or Martian program)
substance circulation based life-support systems will be used.
Such systems will include the higher plants, single-celled seaweed
and other heterotrophs. This creates need for the development
of non-standard technologies for the cultivation and gathering
of food products with improved medicinal and biological values.
Long space expeditions will be subject to high levels of radiation,
which creates the need to develop new methods of radiation shielding.
Besides, cosmonauts, being only human, can be exposed to diseases.
The search for methods that increase the efficiency of the immune
systems of cosmonauts is one of the major factors in lengthy
space expeditions. .
In the State Scientific Center of Russian Federation-Institute
for bio-medical problems of the Russian Academy of Sciences
long term research has shown that in the solution of these problems
deuterium free water shows promising results and has positive
medicinal and biological qualities. With this goal in sight
we have developed the technology for its obtainment, based on
the electrolysis of distilled water with the subsequent transformation
of received gases (hydrogen and oxygen) in water with the lowered
concentration of deuterium. In the first stages of the decomposition
of water on the cathode, a light isotope of hydrogen is formed:
protium, as a result of this oxidation, deuterium-free water
is produced.
Deuterium-free water has been used by us for:
1).
Cultivation of the higher plants,
2).
Breeding of birds . quails,
3).
Research of anti-tumoral properties,
4).
Research of radiation shielding properties.
Cultivation of the higher plants shows that seed production
in higher plants such as the thale cress (Arabidopsis thaliana,
Dijon) and field mustard (Brassica rapa) increases by 150-200%
after being watered with ≪deuterium-free≫ water.
In quails (the Japanese quail: Coturnix coturnix japonica) an
increase in growth rate and organ weight of the birds, in particular
the reproductive organs, is seen.
Research of deuterium-free water as an anti-tumoral substance
showed decrease in growth rates of some tumors, and decreases
in metastasis speed have been revealed, as well as an increase
in the life duration of animals.
Research of radio-protective properties of ≪deuterium-free≫
water has shown that its consumption by animals, irradiated
with gamma rays from Cobalt-60, led to increased life duration,
and a decrease in speed and count of cataract formations in
the eyes.
In long space flights deuterium-free water can be received with
the use of regeneration systems from a condensate of atmospheric
moisture, urine and other sources.
The results of the research received while developing space
life-support systems can be used in medicine, fundamental biology,
agriculture and other areas of science.
Protective Effects of DDW in a C.elegans model
1Avila D.S., 2Somlyai
G, 1Aschner M
1Vanderbilt Medical Center, Nashville
TN, USA
2HYD LLC for Cancer Research and Drug
Development, Budapest, Hungary
The nematode Caenorhabditis elegans is a unique model organism
for studies on longevity and the aging process. The worm is
an attractive system because of its size (1mm in lenght), short
life span (~ 20 days) and its homology to the human genome (60-80%).
The knowledgebase obtained through genetic analyses strongly
suggests that endocrine signalling plays a key role in many
of the pathways that alter the aging process in C. elegans,
including insulin/IGF-1-like signalling. In order to study the
putative anti-aging effects of depleted deuterium water (DDW),
we used a well-standardized manganese (Mn) model of toxicity
in C.elegans, in which it has been demonstrated that Mn causes
lethal osmoregulation defects, developmental delay, dopaminergic
neurodegeneration and decrease in lifespan. In the present study
we analyzed the ability of DDW to attenuate the Mn-induced effects.
A synchronous population of N2 (wild type) worms was treated
with 35 mM MnCl2 (4000 worms per tube in) for 30 minutes and
then washed 3 times to remove residual Mn. Next, worms were
treated for 48 hrs with a D-concentration of 150 ppm (M9 buffer
in regular water), 120 ppm (M9 buffer prepared with DDW in a
ratio 25: 75 of M9 in regular water) or 90 ppm DDW (M9 buffer
prepared with DDW in a ratio 50: 50 of M9 in regular water).
After the treatment, worms were washed and placed on plates
for life span assay or prepared for protein extraction and immunoblotting.
We observed that Mn caused a shortened lifespan in worms, which
was reversed by DDW (120 and 90 ppm). As lifespan is a direct
measurement of aging and as DDW showed this anti-aging property,
we decided to study the DAF-16 pathway in Mn/DDW treated animals.
Interestingly, we observed that DDW was able to restore the
DAF-16 expression that had been reduced by Mn exposure. In addition,
superoxide dismutase (SOD) and AKT, downstream and upstream
proteins in the DAF-16 pathway respectively, were altered by
Mn exposure; however, their expression was also restored by
DDW treatment. Taken together, these results demonstrate that
DDW may play a protective role against Mn toxicity and aging,
likely by attenuating Mn-induced reactive oxygen species generation.
The effect of DDW is likely mediated by the DAF-16 pathway,
as a transcriptional factor that increases the expression of
antioxidants proteins and increase the lifespan in C.elegans.
Further studies are necessary in order to clarify the exact
molecular mechanisms of the anti-aging activity of DDW, especially
whether it is only related to the DAF-16 pathway. Keywords:
DDW, manganese, C.elegans, aging.
Intermediary Metabolism and Macromolecule Synthesis in Response
to Deuterium
Depletion in Pancreatic, Breast and Lung Cancer Cell Lines
1L. G. Boros, 2G. Somlyai
1 University of California, SiDMAP LLC.,
Los Angeles, USA
2 HYD LLC. for Cancer Research and Drug
Development, Budapest, Hungary
Hydrogen atoms of water participate in virtually all ion exchange
and substrate . product transport reactions through the cell
membrane and hydrogen also acts as the reducing equivalent in
energy producing as well as reductive macromolecule synthesis
reactions in all living cells. Deuterium depletion of water
in cell culture media or body fluids temporarily decelerates
cell growth in vitro and induces tumor regression in vivo. The
exact mechanism and the effects of deuterium depletion on mammalian
cell intermediary metabolism are not fully known. Potential
mechanisms of carcinogenesis include the following: 1) Deuterium
incorporation from common water into DNA increases its fragility
thus accelerates mutations, aging and cancer; 2) Deuterium affects
the kinetics of reductive synthesis and the generation of NADP+
thus altering membrane fatty acid and cholesterol synthesis;
3) Deuterium alters tricarboxylic acid cycle and intermediary
metabolism by altering carbon flow and the rate of product synthesis
and energy production. Stable isotope-based metabolic profiling
studies were performed to determine metabolic flux-modifying
effects of deuterium depleted water (DDW: 100, 50 and 25 ppm)
as compared to normal deuterium-containing water (150ppm) on
[1,2-13C2]-D-glucose metabolism in cultured pancreatic (MIA-PaCa),
lung (H-441) and breast (MCF-7) ductal carcinoma cells. Deuterium
depleted water (DDW) did not significantly alter glucose uptake,
oxidation and glycogen synthesis in any of the cell lines. Pentose
cycle flux relative to glycolysis decreased in MIA-PaCa cells.
RNA ribose synthesis and turnover also decreased in MIA-PaCa
cells after 25 ppm treatment. TCA cycle substrate flux decreased
in MCF-7 breast tumor cells. Lignocerate (C:24) and palmitate
syntheses were decreased in MIA-PaCa cells and cholesterol synthesis
was decreased in MCF-7 breast tumor cells. Based on these observations
it is evident that decreased deuterium to hydrogen ratios regulate
sterol and fatty acid precursor synthesis, which likely affects
the rate of divisions and cellular proliferation via limited
reductive synthesis and new membrane formation.
Cell
physiological effects of reduced deuterium content in the leaves
of Elodea canadensis
Gabor Laskay
Department of Plant Biology, University of Szeged, Szeged, Hungary
The effect of reduced deuterium (D) concentration of water was
studied on several important cell physiological parameters in
intact isolated leaves of the aquatic macrophyte Elodea canadensis
by incubating the leaves in nutrient solutions prepared with
distilled water having natural (150 ppm) or low (87 ppm) concentration
of D in the presence of light. In normal water Elodea leaves
induced a gradual alkalinization of the external medium, whereas
in low-D water an external acidification was detectable in the
first 30 minutes, the rate of which decreased gradually, and
after about 2 hours the external alkalinization recovered to
a rate similar to that of the control. Associated fluorimetric
studies using the potential-sensitive fluorescent probe 3,3’-dipropylthiacarbocyanine
(di-S-C3-(3)) revealed an increase in the dye fluorescence,
indicative of a higher resting membrane potential (hyperpolarization)
of the cells. Since the time-course of the hyperpolarization
and that of the external acidification was comparable, they
both could be associated with an increased activity of the H+-ATP-ase
present in the plasma membrane of the cells. These observations
demonstrate the ability of Elodea cells to detect and respond
to a reduction in the D-concentration of water. It is concluded
that a sudden perturbation of the pre-existing intracellular
D/H ratios might be responsible for the observed cellular responses.
Importantly, these responses are of transient nature, and the
physiological processes of the plant cells adapt to the altered
conditions within hours.
Antiproliferative effects, cell cycle alterations and apoptosis
induction of DDW on T47D and HT-29 human
carcinoma cell lines.
1,2E. Azizi, 3K.
Akbarzadeh, 4A. Hosseini
1Molecular Research Lab, Department of
Pharmacology and Toxicology, Faculty of Pharmacy, 2Department
of Medical Biotechnology, School of Advanced Medical Sciences,
Tehran University of Medical Sciences (TUMS), 3Biological Effects
of Deuterium Research Center, Atomic Energy Organization (AEO),
4Office of Pharmaceutical Research and Development, Food and
Drug Administration, Ministry of Health and Medical Education
(MOHME), Tehran, Iran Cancer therapy is still a major obstacle
among medical oncologists around the world. Failure in chemotherapy
of tumor cells is mainly related to occurrence of drug resistance.
Cell cycle alterations and or decreased apoptosis induction
following chemotherapy are primarily due to molecular changes
of cancer cells. Studying new compounds alone or in combination
with potent chemotherapeutic drugs such as Doxorubicin can open
new strategic approach in cancer therapy. Previous reports indicated
the potential anticancer effects of Deuterium Depleted Water
(DDW). Therefore, we studied the antiproliferative effects of
2 types of DDWs (A and B) produced by AEO on human breast T47D
and colorectal HT-29 carcinoma cells in comparison to Doxorubicin
(Dox) using MTT assay. Cell cycle alterations and apoptosis
induction following exposure of cancer cells to DDWs (A and
B) were also evaluated by flowcytometry using DAPI and Annexin
V-FITC/PI reagents, respectively. Both types of DDWs showed
no apparent effects on proliferation of T47D and HT-29 cell
lines. But the antiproliferative effect of Dox was slightly
increased when prepared in DDWs in comparison to Dox alone.
The S phase in cell cycle pattern of T47D cells was significantly
increased only in Dox prepared in type A of DDW (Dox A). In
the HT-29 cells, the G2/M phase of cell cycle was significantly
increased in both Dox A and Dox B in comparison to Dox alone.
The T47D cells exposed to Dox A and Dox B in comparison to Dox
alone showed increased apoptosis and necrosis, respectively.
Significant increase in apoptosis induction of HT-29 cells was
observed following exposure to Dox A and Dox B in comparison
to Dox. In conclusion, these data supports the previously reported
findings on significant potential of DDWs on cancer cells to
enhance the effectiveness of chemotherapy.
Keywords: Cancer therapy, DDW, T47D, HT-29, Cytotoxicity, Cell
Cycle, Apoptosis
Studies concerning DDW use for deuterium’s depletion in animal
organism and for synthesis of new naphthoquinonic antitumoral
compounds
I..tef.nescu1, T. Nicola2,
C. Mladin3, R. Tamaian1,
V. Niculescu1, V. Feurdean4,
G. Ti.escu1, N. P.un1
1National Research and Development Institute
for Cryogenics and Isotopic Technologies, Rm.Valcea, ROMANIA,
2Municipal Hospital, Timi.oara, ROMANIA, 3S.C. Mecro System
S.R.L. Bucharest, ROMANIA, 4National Institute for Research
and Development of Isotopic and Molecular Technologies, Cluj-Napoca,
ROMANIA
Until the 90’s, it didn’t exist the possibility to reduce the
quantity of deuterium in external or internal medium of living
organisms. With the discovery of DDW (deuterium depleted water
or light water), it was obtained a rapid and easy way to reduce
deuterium in biological systems by the simple administration
in the development medium or in drinkable water of deuterium
depleted water. In our studies we used DDW produced at our institute
(patent WO/2006/028400: PCT/RO2005/000011 . Process and installation
for obtaining the deuterium depleted water), which is the main
ingredient for the commercial product QLARIVIA.. The experiments
followed two main directions: the first one was about monitoring
deuterium’s concentration decrease in animal’s body using DDW
as depleting agent; the second one consisted in the synthesis
of new antitumoral compounds derivated from 1st International
Symposium on Deuterium Depletion 15 naphthoquinone ligands using
DDW as solvent. Literature mentioned the antiproliferative and/or
antitumoral effects [1,2,3,4] of DDW, but without showing the
comparative deuterium ratio in normal condition and after administration
of DDW. In this respect, our deuterium depletion studies were
carried out on laboratory and farm animals, nourished with standard
food and drinking water (witness lot) and DDW (experimental
lots). Biological samples (liquid and solid samples) were analyzed
by massspectrometry. These new synthesized antitumoral compounds
consist in metal complexes with naphthoquinone derivatives.
In the process of synthesis, DDW was the solvent for transition
metals (Ni, Cu,Co) salts in order to decrease the deuterium
content of our new compounds. The result of first experimental
series shows that in natural conditions, the organism has the
tendency to accumulate deuterium through bioaccumulation process.
On the other hand, the grade of deuterium depletion seems to
be under influence both of specimen genotype and behavior, and
also of deuterium’s depleting medium concentration . moreover,
this effect is time dependent. The result of second experimental
series was the obtaining new types of anticancer compounds with
low deuterium content for in vitro and in vivo future experiments.
As a conclusion, DDW can be used as a synergic agent for deuterium
depletion in both biological assays and chemical processes for
a possible combined anticancer therapy.
The
effects of administration and local application of deuterium-depleted
water on dogs and cats suffering from spontaneous malignancies
1M. Szabo, 2T.
Berkenyi, 3G. Somlyai
1Veterinary Center, Budapest, Hungary,
2Alpha-Vet Veterinary Hospital, Szekesfehervar, Hungary, 3
HYD LLC for Cancer Research and Drug Development, Budapest,
Hungary
Dogs and cats bearing malignant tumors were given Vetera-DDW-25R
A.U.V. deuterium-depleted water (DDW) containing deuterium
(D) at a concentration of 2.8 mmol/L (25 ppm) instead of normal
tap water, which contains 16.8 mmol/L D (150 ppm). The DDW
therapy was combined with surgery when conditions were sufficient
for the excision of the tumor or DDW was applied as a single
treatment in numerous cases. Mammary tumors in 81 dogs and
14 cats showed a response rate higher than 70%; more than
50% of the animals achieved complete recovery. Similar effectiveness
was observed in 43 dogs and 3 cats bearing rectal tumors.
More than 70% of cats with lymphoid leucosis achieved complete
response. Sarcomatoid tumors in dogs showed a shortterm response
or no response at all.
As a result of DDW consumption, a gradual decrease of the
serum D-concentration was detected in dogs and cats during
the 12-week DDW treatment, which was restored when DDW intake
was replaced again with ordinary tap water.
The gradual decrease of serum D-concentration raised the question
whether it is possible to increase the effectiveness of DDW
if we can reach a more rapid decrease in D-concentration especially
in certain types of tumors, such as ulcerative, extensive,
relapsed, metastasizing tumors, malignant melanoma, and sarcomatoid
tumors which were fairly resistant to per os (PO) DDW treatment.
In order to get a sharp decrease in D-concentration a new
injectable formulation of DDW was developed. Dogs affected
with malignant tumors of poor prognosis were submitted to
treatment with DDW injections. Local treatment induced regression
of tumors that were resistant to previous PO DDW administration
and produced advantageous conditions for subsequent surgical
interventions. Microscopic evaluations of the tumors verified
that DDW injection induced disappearance of tumor cell infiltration,
demarcation and consequent rejection of invasive tumors, nevertheless,
DDW injections were harmless to healthy tissues in the environment
of the tumor. Simultaneous PO and local treatment was initiated
in some animals to enhance therapeutic effectiveness and to
prevent relapses. As a result of the combined treatment, dogs
became tumor-free and asymptomatic and 3 to 3.5 years after
therapy they were still alive. DDW injection alone or in combination
with surgery offers an effective cancer treatment of aggressive
tumors with poor prognosis.
Effect of deuterium oxide (D2O) content
of drinking water on glucose metabolism in STZ-induced diabetic
rats
1M. Molnar, 1K.
Horvath, 1T. Danko, 2G.
Somlyai
1Semmelweis University Inst. Pathophysiology,
Budapest, Hungary
2HYD LLC. for Cancer Research and Drug
Development, Budapest, Hungary
Deuterium, a stable isotope of hydrogen, binds to oxygen to
form D2O. D2O
exist in the environment at 1/6700 of H2O
(150 ppm) and is expected to have some biological effects.
Several lines of evidences suggest that D2O
inhibits insulin release from pancreatic islets. Very little
or no data is available on the action of lowering D2O content
of the cellular environment. Some experimental and clinical
observations suggest that depletion of D2O
has anti-mitotic effect in various tumor cells. Some clinical
observations also suggest that depletion D2O
interfere with glucose metabolism in diabetic patients. In
our experiments we wanted to test the effect of removal of
D2O on the glucose metabolism in sreptozotocin
(STZ)-induced diabetic rat model. Diabetes was induced by
a single ip. injection of 60mg/kg body weight of STZ. After
2 weeks, animals were randomly distributed into several groups
to test the effect of D2O (25-150 ppm)
on glucose metabolism in diabetic animals with or without
2x1 U/day insulin treatment. The following parameters were
tested: serum glucose, -fructose amine, -HbAIC, -creatinine,
-TBARS and -insulin; urine glucose, -creatinine and -protein.
At the end of the experiments, 8 weeks of treatment, membrane
associated GLUT-4 content was estimated by western-blot technique
from m. soleus. Our results indicate that STZ treatment significantly
increased serum glucose, fructose amine, HbAIC and TBARS concentration.
Depletion of D2O did not influence any of the measured parameters
in animals 16 1st International Symposium on Deuterium Depletion
not received insulin. However the measured parameters were
significantly lower in those animals received lower D2O
containing drinking water and insulin treatment. The membrane
associated GLUT-4 was significantly higher in these animals
also. These data suggest that D2O depletion
enhance insulin effect on GLUT-4 translocation and potentiate
glucose uptake in iabetic animals. The mode of action of D2O
depletion is not fully understood and needs further experiments
to elucidate this question.
Deuterium
depletion as an effective treatment option for prostate cancer
. Statistical evaluation of a double blind, randomized phase
II clinical trial and a retrospective study on prostate cancer
1G. Somlyai, 2I.
Guller, 1K. Krempels, 1I.
Somlyai, 2A. Kovacs
1 HYD LLC. for Cancer Research and Drug
Development, Budapest, Hungary, 2Saint
John’s Hospital, Budapest, Hungary
In order to investigate whether DDW might exert an anticancer
effect in humans and improve the results of conventional treatments,
a four-month long double blind, phase II, placebo controlled
clinical trial was conducted on prostate cancer. In addition,
beside the 44 evaluated patients in the phase II clinical trial,
the course of the disease was also retrospectively evaluated
in 91 patients consuming DDW parallel with the conventional
forms of treatments.
Summarizing the changes in prostate volume during the 4 months’
period of the phase II clinical trial in the treated group a
net decrease of 160.3 cm3 was achieved, on the contrary, the
result was 54 cm3 in the control group. Furthermore, in those
7 patients, who achieved PR (p=0.046), the prostate volume became
smaller by 125.2 cm3 in total, and the patients reached 32%,
64%, 18%, 70%, 47%, 20%, and 52.6% decrease respectively in
comparison to the size detected at entering the trial. One patient
showing PR in the control group achieved 13.4 cm3 (59%) decrease.
Urination complaints ceased in 8 patients of the treated group,
but none of the patients experienced changes in their complaints
in the placebo group (p=0.0041). During the extended follow-up
of the 44 patients, in the first year (from the date of entering
the trial), 2 patients (9.1%) died in the treated group and
9 patients (40.9%) in the placebo group (significantly lower
mortality in the treated group; Fisher’s Exact Test, p=0.034).
The cumulative time of DDW consumption of the retrospectively
evaluated 91 patients was 139.2 years. The time period from
the initial diagnosis to the end of the follow-up was 350.1
years. The median survival time (MST) of the 91 patients was
11.02 years although 46 of them (50.5%) had distant metastasis
either before the start of the DDW treatment or after that.
Due to the extremely low death rate (4 patients, 8.8%) in spite
of the 157 years cumulative follow-up period in the population
without distant metastasis, we could not calculate the MST.
Investigating the patients with distant metastasis developed
within one year after the diagnosis, the MST was 5.4 year (64.8
months) suggesting that the administration of DDW may had an
effect resulting in longer MST comparing to other studies with
progressive metastatic prostate cancer showing 15-20 months
long MST. The results suggest that DDW might reduce the mortality
of prostate cancer, since it was able to delay progression as
well as to prolong MST in patients with histologically confirmed
prostate cancer.
A Retrospective Study to Evaluate the Effect of Deuterium
Depletion on the Survival of Metastatic Breast Cancer Patients
K. Krempels, I. Somlyai, M. Huszar, G. Somlyai
HYD LLC. for Cancer Research and Drug Development, Budapest,
Hungary
Breast cancer is one among the most prevalent forms of malignant
tumors worldwide. Development of locally advanced, recurrent
and/or metastasizing disease is the primary determinant of the
outcome and represents a high risk for breast cancer patients.
The anticancer effect of deuterium depleted water (DDW) has
been revealed in the treatment of spontaneous malignancies in
dogs and cats. The therapeutic efficacy of per os (PO) DDW treatment
was also confirmed in a human, phase II double blind clinical
trial on prostate cancer. The aim of the present study was to
investigate the impact of DDW consumption in addition to conventional
forms of treatments on the survival of metastatic breast cancer
(MBC) patients. The records of 74 women suffering from MBC were
retrospectively evaluated for the period between January 1993
and May 2005 and all but 6 of the 74 patients had previously
undergone intensive and repeated prior conventional therapy
and had limited expectations on survival time In the 74 patients
135 distant metastases were diagnosed before DDW treatment commenced..Conventional
cancer therapy was supplemented with PO DDW treatment; i. e.
daily water intake of the patients was replaced by DDW. DDW
consumption and simultaneous conventional treatment elicited
response or halted tumor growth in 74.3% of the 74 MBC patients.
Median survival time (MST) from the diagnosis of the distant
metastasis was 47.7 months. Probability for 1-, 2-, 5-, and
8-year-long survivals were 93.7%, 77.8%, 33.4%, and 9.1%, respectively.
The subgroup of patients achieving complete (CR), or partial
response (PR) had MST of 63 and 50 months, respectively, while
the subgroups showing no change (NC) or progression of disease
(PD) reached a MST of 35 and 31 months respectively. Taking
the amount and the D-concentration of the DDW consumed, the
lengths of the treatment and body weight into consideration,
a new parameter called deuterium depletion unit (DdU) has been
introduced. Frequency of CR and PR was significantly higher
(p=0.0028) in patients consuming DDW at a dose higher than 1
DdU and borderline significant results (p=0.046) were achieved
when deuterium depletion reached 0.6 DdU. The great majority
of the patients whose disease progressed or showed no change
consumed DDW at a low dose and/or at irregular intervals.
Application of DDW as an oral anticancer agent simultaneously
with the conventional forms of treatment remarkably prolonged
MST: it produced twice to three times longer MST in patients
achieving CR or PR. We suggest that DDW can be integrated in
the conventional treatment regimens of MBC patients.
Lung
cancer and deuterium depletion. Clinical and experimental
data.
Z. Gyongyi, I. Szabo, F. Budan
Department of Public Health & Preventive Medicine, University
of Pecs, Pecs, Hungary
In spite of the development of the therapies, the shortness
of the survival of lung cancer patients is still remained
disappointing. In this manner finding new adjuvant strategies
is in the focus of cancer cure. Deuterium depletion represses
cell division in plants and suppresses some genes, which are
involved in tumour formation. In this experiment we compared
expressions of genes, which are involved in lung cancer development
to clinical outcomes of lung cancer patients consuming deuterium
depleted water. In animal experiment, carcinogenic DMBA was
applied to induce over-expression of p53, bcl-2 and Kras in
lung tissue of mice, while animals drank deuterium depleted
water. In clinical study, 129 patients received diverse chemotherapy
and radiotherapy and drank deuterium depleted water as an
adjuvant, non-toxic therapy. Deuterium depleted water could
significantly diminish DMBA-induced expression of p53, bcl-2
and Kras in the lungs of mice. Within patents, median survival
was 25.7 months, CI [22.3; 29.1] in men and 73.6 months, CI
[50.6; 96.7] in women with statistically significant difference.
Median survival of subjects with brain metastasis was 26.9
months, CI [20.9; 32.9]. Cumulative 5 year survival probabilities
were 15 %, 60 % and 26 % in male, female and patients with
brain metastasis respectively. Deuterium depletion could prevent
the DMBA-induced over-expression of p53, bcl-2 and Kras genes
as an anti-carcinogenic agent in animals and could extend
survival of lung cancer patients as an anticancer adjuvant
therapy especially within women maybe because of suppression
of cancer-related genes.
Main results and basic rules of the human application of
deuterium depleted water in combination with conventional
therapies
G. Somlyai, I. Somlyai, M. Huszar, K. Krempels
HYD LLC. for Cancer Research and Drug Development, Budapest,
Hungary
Beside the phase II clinical trial, that had been conducted
with 44 prostate cancer patients, a data base has been created
from 1992 involving all those patients who had been subjected
to the administration of deuterium depleted water (DDW) for
at least one day. This data base refers to 1,969 patients
(949 male and 1020 female patients), who fulfilled this main
criterium between October 1992 and April 2010.
The cumulative time from diagnosis to the end of the follow-up
period was 5,136 years, from the start of DDW consumption
to the end of the follow-up, this value was 2,692 years. The
cumulative time of DDW administration was 1,892 years. The
median age of the investigated population was 55 years. The
evaluated 1,969 patients represented 59 different localizations
of the tumor. The incidence of the main tumor types among
the examined patients was almost identical with the same data
of the National Cancer Registry.
The median survival time (MST) of the whole test population
was 7.7 years. Investigating the length of MST and the duration
of DDW consumption, a strong correlation was found. MST was
calculated for the sub-groups of patients consuming DDW for
0-3, 3-6, 6-12, 12-24 and longer than 24 months and an MST
of 0.7, 4.5, 5.8, 9.9 and 17.8 years was found, retrospectively.
583 patients died (303 males and 280 females) out of 1,969
during the follow-up period. 59.3% of the patients died within
6 months, 36.1% within 3 months after the start of DDW consumption.
Investigating the possible causes of unsuccess in these cases
we found that the median time of DDW administration was only
37 days in patients consuming DDW for not longer than 3 months,
while it was 288 days in those sub-group where patients consumed
DDW for longer than 3 months, suggesting that the length of
DDW administration is a determinative factor influencing the
outcome of the disease.
There was a sub-group of patients (99), who, in most cases,
interrupted the use of DDW after its long-term consumption,
but later on they started again and repeated the cures in
spite of the fact, that they were in remission. The median
time from the diagnosis to the start of DDW was 174 days,
the length of DDW consumption was 1,015 days. Since only 8
patients died in this sub-group during the 585 years’ cumulative
survival time of the follow-up period from the diagnosis,
it was not possible to calculate the MST because of the extremely
low death rate.
We conclude that the integration of DDW treatment into the
conventional oncotherapies may increase the MST of cancer
patients. The efficacy of DDW depends on the length of DDW-treatment.
Based on the statistical analysis of homogenous populations
of metastatic breast-, lung-, and prostate cancer patients
has been carried out earlier, and the present evaluation of
the data of 1,969 patients using DDW, we conclude, that through
the integration of DDW into the widely accepted and applied
oncotherapies a 2-3 fold increase may be achieved in the MST
of cancer patients suffering from the most common tumor types.
|
|
|
|
|
Connections2000
Event and Incoming Agency
H-1016 Budapest,Hegyalja ut 18.
Phone:36-1-209-0380, Fax:36-1-209-9334
conn2000@conn200.hu
www.conn200.hu
|
The
main activities of iur Connections2000 Event
and Incoming Agency,which has been working for
10years, are comprehensive preparation, organization
and arrangement of conferences, international
congresses, doctor-patient appointments, press
conferences, trainings,banquets, social events
and incoming programs into Hungary.
We do our job according to the below professional
criteria:
・Implementing
the professional objectives and representing
the business interests of our clients
・References,personal
business connections
・Reliability,
commitment to quality service
・Comprehensive
organizational activity
・Management
of sponsorship
・Professional
experience of several years, operational values
・Creative
event organization, selecting the premises
・Preference
of price-value ratio
Nowadays, the most efficient way to make an
organization's important event memorable is
to compose it from the beginning till the end,
to draw the participants' attention and interest.
The event is successful if
・the
set objectives can be achieved by it
・both
our client and the participants are satisfied
・it
is original, well-organized and neatly arranged
・it
represents the personality and image of the
professional host.
Success is attributed to the client.
The main task of a professional event organizer
is
・to
take care of every single detail, to provide
attention and a solid background
・form
the creative event organization
・through
reasonable prices
・to
the smooth and flawless completion
・of
a successfull event.
Our event organizing team has several years
of experience in the field of medical conferences,
congresses and trainings. We help the organizing
committee's work in a flexible way, adapting
to the special assignment, form planning till
completion of the event.
Please find below our references of medical
professional events in the past few years:
・EULAR
Autumn Conference for PARE-2008
・Hungarian
Cancer Society-Nursing Session I.Roving Conference
and Exhibition-2008
・International
World Day of Nursing-Record Day of Oncological
Nurses-2008
・XXVII.
Congress of Hungarian Cancer Society-2007
・"Kekgolyo"
Days 2007 National Conference and professionsl
Exhibition for Oncological Nurses-2007
・19th
Meeting of the European for Association for
Cancer Research-2006
・NEW
HORIZONS in Treating Cancer 4th International
Conference for Organizations Representing People
with CML or GIST-2006
・Biennal
Congress of European Society of Surgical Oncology-2004
Further infomation and references can be obtained
on our up-dated website:www.conn2000.hu
Please contact us, so htat we can release you
from the problems of event organization and
background activities, and so that we can present
you with the joy of a successful professional
event.
|
|
Connections2000
Event and lncoming Agency
H-1016 Budapest, Hegyalija ut
18. Phone:36-1-209-0380, Fax:36-1-209-9334
www.conn2000.hu, conn2000@conn2000.hu
|
|
|